
Opinion|Videos|March 12, 2025
MIUC: Risk of Recurrence After Radical Cystectomy
Author(s)Matthew Galsky, MD
An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a significant recurrence risk. High-risk factors include advanced stage, lymph node involvement, and positive surgical margins. Neoadjuvant cisplatin-based chemotherapy can improve survival but does not eliminate recurrence risk. Other predictors include lymphovascular invasion, variant histology, and systemic inflammation markers.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- What is the risk of recurrence for patients with muscle-invasive urothelial carcinoma who undergo radical cystectomy with or without neoadjuvant cisplatin-based chemotherapy? (Renner 2021; Kim 2015; Bellmunt 2022)
- What factors put patients at higher risk for recurrence?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















